China Life Science Sector Overview 2022: Wading into Deep Waters: Survive and Thrive

January 30, 2023 | BY

Susan Mok

The Chinese government has been deepening its reform over the past year in order to foster evolving regulatory framework. Deeper reforms coupled with a chilled market means life science companies should prioritize their assets and re-position their business strategies in order to survive and grow stronger.

Summary

|
  • Innovation-driven regulatory environment and economic downturn in the past year have urged life science companies to be more resilient and flexible to current regulatory and market changes.
  • The Chinese government has cultivated an innovation-driven regulatory environment and provide unprecedented market incentives for orphan drugs and pediatric drugs.
  • The legislative development in 2022 addressed various emerging issues in the industry, including cell and gene therapy regulation, cross-region or cross-border regulation, e-commerce regulation.

The legislative developments in 2022 continued to reinforce and foster the spirit and regulatory framework laid by the PRC Drug Administration Law (DAL) (中华人民共和国药品管理法), the PRC Vaccine Administration Law (VAL) (中华人民共和国疫苗管理法), the PRC Medical Device Regulation (MDR) (医疗器械监督管理条例) and the Regulations for the Supervision and Administration of  (CSAR) (化妆品监督管理条例) between 2019 to 2021 to cultivate an innovation-driven environment and compliance culture for the life science sector.

I

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]